Authors

Latest:

Dr. Kozuch on the Evaluation of ctDNA in the CIRCULATE-US Trial in Resected CRC

Peter Kozuch, MD, discusses the phase 2/3 CIRCULATE-US trial evaluating chemotherapy decisions for patients with resected colorectal cancer based on circulating tumor DNA status.

Tamas A. Gonda, MD

Latest:

Leveraging Endoscopic Ultrasound in Pancreatic Cancer: Looking to the Future

In this final episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, reiterate that the role of endoscopic therapies in pancreatic cancer continues to evolve.

Aristotelis Bamias, MD

Latest:

Dr. Bamias on Final Analysis of Atezolizumab Monotherapy in the IMvigor130 Trial in mUC

Aristotelis Bamias, MD, discusses key efficacy data from a final analysis of the phase 3 IMvigor130 trial in metastatic urothelial carcinoma.

Angeles Alvarez Secord, MD, MHSc

Latest:

Dr Secord on the National Academies of Sciences, Engineering, and Medicine’s Assessment of Women’s Health Research at the NIH

Angeles Alvarez Secord, MD, MHSc, discusses findings from the consensus report published by the National Academies of Sciences, Engineering, and Medicine committee.

Jennifer Crombie, MD

Latest:

FDA Approval Insights: Epcoritamab in Relapsed/Refractory Follicular Lymphoma

Jennifer Crombie, MD, shares insights about the FDA's approval of epcoritamab for patients with relapsed/refractory follicular lymphoma.

Samuel Kareff, MD, MPH

Latest:

The Importance of Hematology/Medical Oncology Fellowship

Samuel A. Kareff, MD, MPH, shares his reflections on the benefits, challenges, and critical elements of effective mentorship in hematology/oncology.

Barbara Melosky, MD, FRCPC

Latest:

Dr. Melosky on the Use of Lurbinectedin in SCLC

Barbara Melosky, MD, FRCPC, discusses the use of lurbinectedin in small cell lung cancer.

Cassandra A. Hathaway, MD

Latest:

Dr Hathaway on the Investigation of Distress on the TME in Ovarian Cancer

Cassandra A. Hathaway, MD, discusses the rationale for investigating the association between distress, such as depression, and the tumor immune microenvironment in patients with ovarian cancer.

Michael Chuong, MD, FACRO

Latest:

Dr Chuong on the Patterns of Guided Radiation Therapy in Pancreatic Cancer

Michael Chuong, MD, FACRO, discusses patterns of locoregional recurrence following guided radiation therapy in pancreatic cancer.

Callie Coombs, MD

Latest:

Dr Coombs on Notable BTK Inhibitor Combination Studies in CLL

Callie Coombs, MD, discusses the investigation of notable BTK inhibitor combination trials in patients with chronic lymphocytic leukemia.

Andrew S. Brohl, MD

Latest:

Dr Brohl on the Safety and Efficacy of IFx-Hu2.0 in MCC and CSCC

Andrew S. Brohl, MD, discusses the safety and immunologic responses with intratumoral administration of Idx-Hu2.0 in patients with advanced Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Konstantinos Arnaoutakis, MD

Latest:

Dr. Arnaoutakis on the ADAURA Trial Examining Osimertinib in EGFR-Mutant Lung Cancer

Konstantinos Arnaoutakis, MD, discusses the phase 3 ADAURA trial examining osimertinib in the adjuvant treatment of patients with EGFR-mutant lung cancer.

UC Irvine Health

Lewis Au, MBBS, BMedSci, FRACP

Latest:

Dr. Au on the Results of a Subgroup Analysis Evaluating Antibody Response to COVID-19 in Cancer

Lewis Au, MBBS, BMedSci, FRACP, discusses the results of a subgroup analysis evaluating antibody responses to COVID-19 in patients with cancer.

Devika Das, MD, MSHQS

Latest:

Dr Das on the Use of Neoadjuvant and Adjuvant Chemoimmunotherapy Regimens in NSCLC

Devika Das, MD, MSHQS, discusses the use of neoadjuvant and adjuvant chemoimmunotherapy for patients with resectable non–small cell lung cancer, and emphasizes the importance of multidisciplinary collaboration when incorporating these regimens into treatment approaches.

John M. Burke, MD, Rocky Mountain Cancer Centers

Latest:

Dr Burke on Challenges Associated With Initiating Venetoclax in Patients With CLL

John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.

Caicun Zhou, MD, PhD

Caicun Zhou, MD, PhD, is the director of the Department of Oncology at Shanghai Pulmonary Hospital, and director of the Cancer Institute at Tongji University.

Latest:

Dr Zhou on Frontline Ivonescimab vs Pembrolizumab in PD-L1+ Advanced NSCLC

Caicun Zhou, MD, PhD, discusses data for ivonescimab vs pembrolizumab as first-line treatment for patients with PD-L1–positive advanced NSCLC.

Arnulf Stenzl, MD

Latest:

Dr. Stenzl on Future Research With Enzalutamide in Prostate Cancer

Arnulf Stenzl, MD, discusses future research efforts with enzalutamide in prostate cancer.

Xiaojia Wang, MD

Xiaojia Wang, MD, is an oncologist in the Department of Breast Medical Oncology at the Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital and a key researcher at the Institute of Cancer and Basic Medicine (IBMC) at the Chinese Academy of Sciences in Hangzhou, China.

Latest:

Dr Wang on Updated Efficacy and Safety Data With First-Line Ivonescimab Plus Chemotherapy in TNBC

Xiaojia Wang, MD, shares responses achieved with the combination of ivonescimab plus chemotherapy in locally advanced unresectable or metastatic TNBC.

Michael Smylie, MBBS, FRCPC

Latest:

Considerations for Taking Oncology Care "to the Ends of the Earth": With D. Ross Camidge, MD, PhD; and Michael Smylie, MBBS, FRCPC

Drs Camidge and Smylie discussed Dr Smylie’s experience treating patients who live in the Northwest Territories of Canada.